

PATENT

Attorney Docket No. 27013/38150

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Gissmann et al.

Application No: 10/042,526

Filed: January 8, 2002

Title: Papilloma Virus Capsomere
Vaccine Formulations and
Methods of Use


Confirmation No.: 9119

Group Art Unit: 1648

Examiner: To be assigned

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service as first class mail, postage prepaid, in
) an envelope addressed to MS Missing Parts,
) Commissioner for Patents, P.O. Box 1450,
) Alexandria, VA 22313-1450 on

) October 13, 2004

) 
) Eric M. Brusca, Ph.D.

) Registration No. 52,664

) Agent for Applicants

**APPLICANT'S RESPONSE TO "NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES"**

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed from the Patent and Trademark Office on August 17, 2004, a copy of which is enclosed herewith.


The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of 37 CFR §1.822 and/or §1.823 for the stated reason that it contained several raw sequence listing errors. Submitted herewith is a substitute sequence listing in both paper and computer readable forms that correct the defects noted in the raw sequence listing report. No new matter has been added to the substitute Sequence Listing.

Respectfully submitted,

MARSHALL, GERSTEIN, & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312)474-6300

October 13, 2004

By:


Eric M. Brusca
Reg. No. 52,664



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

03CD
Box 5a

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/042,526	04/29/2002	Lutz Gissman	27013/38150

04743
MARSHALL, GERSTEIN & BORUN LLP
6300 SEARS TOWER
233 S. WACKER DRIVE
CHICAGO, IL 60606

CONFIRMATION NO. 9119

FORMALITIES LETTER



OC000000013563982

Date Mailed: 08/17/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES***Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in cursive script, appearing to read "Shimada", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE